Ocugen, Inc. (NASDAQ:OCGN) Q4 2022 Earnings Call Transcript

Daniil Gataulin: Congrats on all the progress. Just a couple of follow-ups, one on the cash runway in terms of bundling. Are you expecting to fund the OC 500 series Lexin programs internally or look for external funding? That’s one. And two, in relation to 1010, the 2 INDs that you plan to file this year, are you planning to initiate the actual trials this year as well? Or are you planning to initiate those in 2024?

Shankar Musunuri: The first one is related to Q500 Series emulation vaccines. So as we stated before, we are funding the development of those vaccines and taking it to the clinic. So we’re also in parallel working with various government agencies because of the need, we believe we are trying to secure funding from them. So we do need their support to move them into the clinic. But the development part and preclinical studies, we have budgeted for it and we’re going to complete that — and the second question you had on Q4 10 and OCU410 SD targeting dry AMD and Stroer disease. Those INDs are scheduled to be filed planning in the second quarter of this year. And as soon as we get a positive amount from FDA, we will start dosing patients this year.

Operator: This concludes the Q&A portion. I will now turn the call back over to Chairman and CEO, Dr. Shankar Musunuri.

Shankar Musunuri: Thank you, operator. I’d like to conclude the call with some additional remarks. I think it’s clear that we are staying true to our mission as an integrated patient-centric biotechnology company that targets unmet medical needs. We believe we are in a position of strength, and we are poised to execute our goals with our pipeline for the course of 2023. We look forward to keeping you updated on our programs throughout the year. Thanks for your time today, and have a great week.

Tiffany Hamilton: Thanks, everyone. Have a great day.

Operator: Thank you all for joining today’s meeting. You may now disconnect.